Home
APGE
APGE News

Latest Apogee Therapeutics Inc. (APGE) News on September 16, 2025

Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025

Simply Wall St.

4 days ago

Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

GlobeNewswire

5 days ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

Zacks

3 months ago

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire

4 months ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

Why Is Apogee Therapeutics Stock Trading Higher On Monday?

Benzinga

4 months ago

Why Is Apogee Therapeutics Stock Trading Higher On Monday?

MT Newswires

4 months ago

Apogee Therapeutics Q1 Loss Widens

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

GlobeNewswire

4 months ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

GlobeNewswire

4 months ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade

Zacks

4 months ago

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

GlobeNewswire

4 months ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth

Simply Wall St.

5 months ago

Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth

Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?

Insider Monkey

6 months ago

Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?

MT Newswires

6 months ago

Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Benzinga

6 months ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

MT Newswires

6 months ago

Apogee Therapeutics Full-Year Loss Widens

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

GlobeNewswire

6 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

GlobeNewswire

6 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

Insider Monkey

7 months ago

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

GlobeNewswire

7 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

7 months ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

GlobeNewswire

7 months ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025

Insider Monkey

8 months ago

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

8 months ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

This Apogee Therapeutics Insider Increased Their Holding In The Last Year

Simply Wall St.

9 months ago

This Apogee Therapeutics Insider Increased Their Holding In The Last Year

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 12/17/2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

GlobeNewswire

9 months ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics Advances in I&I Disease Treatments

TipRanks

9 months ago

Apogee Therapeutics Advances in I&I Disease Treatments

MT Newswires

9 months ago

Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

GlobeNewswire

9 months ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces Agenda for Virtual R&D Day

GlobeNewswire

10 months ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

MT Newswires

10 months ago

Canaccord Genuity Initiates Apogee Therapeutics at Buy With $89 Price Target

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

GlobeNewswire

10 months ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

10 months ago

Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans

Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028

TipRanks

10 months ago

Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028

MT Newswires

10 months ago

Apogee Therapeutics' Q3 Net Loss Widens

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire

10 months ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire

a year ago

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

GlobeNewswire

a year ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now

Insider Monkey

a year ago

Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now

MT Newswires

a year ago

Apogee Therapeutics Insider Sold Shares Worth $2,249,307, According to a Recent SEC Filing

Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc

GuruFocus.com

a year ago

Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

GlobeNewswire

a year ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

GlobeNewswire

a year ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

MT Newswires

a year ago

Apogee Therapeutics Insider Sold Shares Worth $1,904,841, According to a Recent SEC Filing

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

GuruFocus.com

a year ago

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)

GuruFocus.com

a year ago

Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)

MT Newswires

a year ago

Apogee Therapeutics Begins Dosing Volunteers in Phase 1 Atopic Dermatitis Trial

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire

a year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

MT Newswires

a year ago

Apogee Therapeutics' Q2 Net Loss Widens

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

MT Newswires

a year ago

Apogee Therapeutics Insider Sold Shares Worth $1,624,764, According to a Recent SEC Filing

Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares

GuruFocus.com

a year ago

Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares

Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)

GuruFocus.com

a year ago

Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE)

GuruFocus.com

a year ago

Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE)

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

GuruFocus.com

a year ago

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

Dow Jones Falls On Jobs Report; GameStop Plunges Ahead Of 'Roaring Kitty' Live Event

Investor's Business Daily

a year ago

Dow Jones Falls On Jobs Report; GameStop Plunges Ahead Of 'Roaring Kitty' Live Event

Can DocuSign's AI offering accelerate growth?

Yahoo Finance Video

a year ago

Can DocuSign's AI offering accelerate growth?

Lab-on-a-Chip and Microfluidics World Congress 2024: 3-Day Conference (Laguna Hills, United States - November 18-20, 2024) Covering Technologies, Companies and Commercialization

GlobeNewswire

a year ago

Lab-on-a-Chip and Microfluidics World Congress 2024: 3-Day Conference (Laguna Hills, United States - November 18-20, 2024) Covering Technologies, Companies and Commercialization

Analysis-Mexico investors worry lopsided vote could threaten rule of law

Reuters

a year ago

Analysis-Mexico investors worry lopsided vote could threaten rule of law

AI Boom Giving Taiwan Semiconductor Sales A Boost

Investor's Business Daily

a year ago

AI Boom Giving Taiwan Semiconductor Sales A Boost

Smart Irrigation Market worth $3.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

PR Newswire

a year ago

Smart Irrigation Market worth $3.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Business Wire

a year ago

Airstar Bank, with AMTD as a co-founder, successfully introduces Futu as A New Shareholder

Taxes Served Corp. Acquires Blue Mountain Bookkeeping LLC to Enhance Tax and Bookkeeping Services

PR Newswire

a year ago

Taxes Served Corp. Acquires Blue Mountain Bookkeeping LLC to Enhance Tax and Bookkeeping Services

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

GlobeNewswire

a year ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire

a year ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire

a year ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

MT Newswires

a year ago

Apogee Therapeutics' Q1 Net Loss Widens

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

MT Newswires

a year ago

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

GlobeNewswire

a year ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns

Simply Wall St.

a year ago

With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns

Paragon’s hub-and-spoke biotech model yields another reverse merger

BioPharma Dive

a year ago

Paragon’s hub-and-spoke biotech model yields another reverse merger

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Zacks

a year ago

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

GlobeNewswire

a year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

GlobeNewswire

2 years ago

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

GlobeNewswire

2 years ago

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m

Simply Wall St.

2 years ago

Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

GlobeNewswire

2 years ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water

Investor's Business Daily

2 years ago

Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water

IPO Stock Apogee Rockets On Solid Phase 1 Outcome

Investor's Business Daily

2 years ago

IPO Stock Apogee Rockets On Solid Phase 1 Outcome

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

GlobeNewswire

2 years ago

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

Apogee data hint at potential for long-lasting eczema drug

BioPharma Dive

2 years ago

Apogee data hint at potential for long-lasting eczema drug

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

GlobeNewswire

2 years ago

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Estimating The Fair Value Of Agilysys, Inc. (NASDAQ:AGYS)

Simply Wall St.

2 years ago

Estimating The Fair Value Of Agilysys, Inc. (NASDAQ:AGYS)

Granite Unveils State-of-the-Art Aggregate Plant

Business Wire

2 years ago

Granite Unveils State-of-the-Art Aggregate Plant

PTC (PTC) Q1 Earnings: What To Expect

StockStory

2 years ago

PTC (PTC) Q1 Earnings: What To Expect

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

CNW Group

2 years ago

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

PacWest Bancorp (NASDAQ:PACW) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

PacWest Bancorp (NASDAQ:PACW) Q4 2023 Earnings Call Transcript

Why Bloomin' Brands, Inc. (NASDAQ:BLMN) Could Be Worth Watching

Simply Wall St.

2 years ago

Why Bloomin' Brands, Inc. (NASDAQ:BLMN) Could Be Worth Watching

Cushman & Wakefield Elevates Sustainability Solutions with Measurabl

Business Wire

2 years ago

Cushman & Wakefield Elevates Sustainability Solutions with Measurabl

BankUnited, Inc. (BKU) Matches Q4 Earnings Estimates

Zacks

2 years ago

BankUnited, Inc. (BKU) Matches Q4 Earnings Estimates

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Associated Banc-Corp Earnings Call

Remitly Global Inc CEO Matthew Oppenheimer Sells 20,832 Shares

GuruFocus.com

2 years ago

Remitly Global Inc CEO Matthew Oppenheimer Sells 20,832 Shares

Associated Banc-Corp (ASB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

2 years ago

Associated Banc-Corp (ASB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ACCESSWIRE

2 years ago

HSN Champions Emerging Designers Through Exclusive Collaboration With Harlem's Fashion Row

Share on Social Networks: